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Summary
Rationale Hepatoid adenocarcinoma (HAC) is an
extrahepatic primary tumor that expresses morpho-
logical features resembling hepatocellular carcinoma.
This rare malignant tumor has been described in the
gastrointestinal (GI) tract, the testes, the ovaries, and
rarely, the lungs. Despite there being no standardized
management protocol for this case with poor prog-
nosis, the literature describes responses to treatment
with cisplatin–etoposide chemotherapy.
Objective We present an updated review of all cases
of HAC of the lung and the favorable results of a novel
management method for this type of tumor.
Results A table including all the HAC of the lung cases
on the electronic database PubMed since 1980 is com-
piled. Here we present a case of primary HAC of
the lungs, initially managed with cisplatin–etoposide
without favorable response to treatment. The im-
munohistochemical profile of the tumor allowed for
the novel use of immunotherapy in the setting of pri-
mary lung HAC, with favorable response.
Conclusion and outlook The case presented here is of
interest as it adopts a novel immunotherapeutic ap-
proach to HAC, yielding a promising outcome. This
highlights the importance of molecular typing and
immunohistochemical profiling in the diagnosis and
management of non-small cell lung cancer.
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Introduction
Hepatoid adenocarcinomas (HAC), first described in
1985 by Ishikura et al. [1], are a rare type of extrahep-
atic alpha-fetoprotein secreting tumor with hepato-
cellular carcinoma (HCC) like morphology. Since that
time, only 33 cases of HAC of the lung have been pub-
lished in PubMed, and the main features of all these
cases are summarized in Table 1.
Two criteria are usually described for the diagnosis
of hepatoid adenocarcinoma, the first being a mixture
of tubular or papillary adenocarcinoma with sheet-
like or trabecular proliferation of neoplastic cells
within an AFP-producing carcinoma. The second
criterion is cells with abundant, eosinophilic cyto-
plasm and centrally located nuclei, in the sheet-like
or trabeculated portion [2]. The immunohistochem-
ical profile of HAC tumors has shown to be variable.
It has been found that 91.6% of HAC tumors stain
positive for AFP [3, 4].
Primary HAC of the lung comprises 5% of all re-
ported cases of hepatoid adenocarcinoma, with the
stomach being the most common site of occurrence
[5]. The literature shows that 100% of HAC stain pos-
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Table 1 Summary of previously reported cases of hepatoid
adenocarcinoma of the lung. Table compiled from adapta-
tion of Grossman, Beasley and Braman (2016) and a PubMed
search (keywords: Hepatoid adenocarcinoma AND Lung be-





Gender Location Size (cm) Smoker AFP level
(ng/uil)
Stage Progression Treatment
Yasunami et al. [7] 1981 67 Male Left Upper Lobe “Fist-sized” Not
given






Yokoyama et al. [8] 1981 69 Male Right Lower
Lobe
11× 11× 7 Not
given
5050 pT3 M1b Not applica-
ble
N/A
Miyake et al. [9] 1986 40 Male Right Upper
Lobe
8× 9× 7 Not
given
3090 pT3M1b Not applica-
ble
Surg




2123 pT2a M1b Not applica-
ble
Surg
Miyake et al. [10] 1987 73 Male Left Upper Lobe 5× 6× 5 Not
given




Okunaka et al. [11] 1992 49 Male Right Upper
Lobe
6× 5× 5 Not
given









Nasu et al. [12] 1997 63 Male Right Upper
Lobe
14× 13× 12 Not
given







2000 82 Male Left Lower Lobe 3.5 Yes Not
Assayed













Hayashi et al. [15] 2002 55 Male Right Upper
Lobe




Hiroshima et al. [16] 2002 71 Male Right Lower
Lobe




















cT2 N0 M0 Liver metas-
tasis
Surg
Ivan et al. [19] 2007 54 Male Left Upper Lobe 13× 11 Yes 14,540 pT4 N3 M1 N/A Chemo,
XRT
Kishimoto et al. [20] 2008 64 Male Left Lower Lobe 7.5× 7× 4 Not
given
673 cT3 N0 M0 Not re-
ported
Surg
Kim et al. [21] 2009 49 Male Left Upper Lobe 6 Not
given
14,707 pT2b N1 Not re-
ported
Surg
Valentino et al. [22] 2012 71 Male Right Lower
Lobe






Lin et al. [23] 2013 66 Male Right Upper
Lobe







Haninger et al. [24] 2014 51 Male Right Upper
Lobe

















Gender Location Size (cm) Smoker AFP level
(ng/uil)
Stage Progression Treatment
































Haninger et al. [24] 2014 60 Male Right Upper
Lobe































Grossman et al. [5] 2016 54 Male Right Up-
per Lobe/
Paratracheal


















Sun et al. [30] 2016 59 Male Right Upper
Lobe
4.5× 3.8× 3.5 Yes Not
assayed
















Basse et al. [32] 2018 43 Not
given












Tx treatment, XRT Radiotherapy, Chemo Chemotherapy, Surg Surgery, AFP Alphafetoprotein
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itive for AFP, CEA, CK18 and CK19 [3]. Furthermore,
a report by Shao et al. [6] extensively discusses the var-
ious management approaches used in previous cases
of HAC of the lung, and concludes that an optimal reg-
iment for the systematic treatment of advanced HAC
of the lung remains elusive.
Case history
A 59-year-old African–American male presented to
the emergency department with right sided chest
pain of recent onset, and numbness in the right up-
per extremity (RUE). The patient is a former smoker
with >30 pack–year history and is currently employed
as a transportation supervisor. The patient’s family
history is significant for colon cancer in the father.
A chest CT showed a 9.3× 7.2× 6.8cm mass located in
the upper lobe of the right lung. The mass presented
with hilar lymphadenopathy. The CT scan did not
exhibit contralateral adenopathy, and the CT-guided
lung biopsy was inconclusive. The patient was sched-
uled for a repeat biopsy and a brain MRI to rule out
brain metastases.
Patient underwent navigational bronchoscopy with
core needle biopsy. The pathological findings were as
follows: poorly differentiated carcinoma with hepa-
toid features. Brain MRI ruled out brain metastases.
The surgical pathology report (processed at the Uni-
versity of Maryland Baltimore Washington Medical
Center Laboratories) reads as follows:
 Fragments of lung tissue showing a poorly differ-
entiated carcinoma consistent with hepatoid carci-
noma
 Tumor cells are positive for CK7 immunohisto-
chemical stain and negative for TTF1, CK5/6
 The PSA, CK20, CDX2, PAX8, GATA3 and PSA im-
munohistochemical stains are non-contributory
 Cytology specimen from 4R Lymph Node aspirate
is positive for HEPAR immunohistochemical stain
consistent with hepatoid carcinoma
PET-CT ruled out a primary hepatocellular carcinoma
and showed a 4.6× 4.4cm left adrenal mass. At that
time, the patient’s symptomatology was significant
for decreased appetite, weight loss of 2kg, and RUE
numbness. Complete blood count was normal. AFP
level was 1.5ng/ml (reference range <10ng/ml). CEA
level was 32ng/ml (reference range <3ng/ml). The pa-
tient was started on a combination of cisplatin and
etoposide chemotherapy.
Tumor was confirmed as primary hepatoid ade-
nocarcinoma of the lung, stage IV-A. TNM staging:
cT4N2M1b: metastases were found in the mediastinal
and hilar lymph nodes and the left adrenal gland. The
immunohistochemical profile of the tumor was ob-
tained: histological grade 3. EGFR negative. ALK-
rearrangement: negative. BRAF w/t. ROS-1: negative.
MSI: unknown. PD-L1 ≥50%. The patient by that time
had received two cycles of cisplatin–etoposide ther-
apy. Symptomatology was significant for decreased
appetite, weight loss of 4kg, and myelosuppression
with an absolute neutrophil count of 600mm3 (refer-
ence range: 1500–8000mm3). TNM stage cT4N2M1b.
Patient was initiated on pembrolizumab and the
combination of cisplatin–etoposide was discontinued
after two cycles. Immunotherapy was well tolerated by
the patient. After 3 cycles of immunotherapy, the CEA
level was 5.3ng/mL, and the complete blood count
was within reference range. The patient did not suffer
from electrolyte abnormalities, and gained 3kg. After
the 5th cycle of pembrolizumab, follow-up CT showed
a reduction of 45% in tumor size. Symptomatology
was relevant for iron-deficiency anemia which is be-
ing treated with iron supplementation. After the 10th
cycle of pembrolizumab, the patient’s CEA increased
to 17.3. Scheduled chest CT showed progression at
the primary site without evidence of progression at
metastatic sites. PET-CT showed a large upper lobe
mass consistent with the patient’s known NSCLC pri-
mary with interval growth of lesion in the right tho-
racic inlet, but with decrease in size and activity of
right hilar lymphadenopathy and left adrenal metas-
tasis. Findings are consistent with a mixed response
but large amount of persistent residual disease.
Patient therapy after 10 cycles of pembrolizumab
has been switched to 3rd line therapy with ramu-
cirumab and docetaxel. Patient’s symptomatology is
negligible.
Discussion
The diagnosis of HAC is a complicated process as it is
difficult to differentiate from metastatic hepatocellu-
lar carcinoma (HCC), even in the absence of a visible
primary tumor in the liver. The data in Table 1 shows
that 21 of the listed patients had their AFP measured
prior to the initiation of treatment. Although 20 pa-
tients presented with elevated serum AFP levels, our
case and the case reported by Grossman et al. [5]
showed normal serum AFP levels. As a result, serum
AFP cannot be used as a diagnostic criterion for HAC.
Furthermore, a study has shown that when the cut-
off value is of 20ng/ml, serum AFP has a sensitivity of
41–65% and a specificity of 80–94% [33]. This low sen-
sitivity indicates that serumAFP level is not reliable for
the detection of HCC. In the setting of an extrahepatic
tumor showing hepatic-like features and an absence
of a primary tumor in the liver on diagnostic imag-
ing, the reported specificity supports the ruling out of
HCC on the basis of negative serum AFP test. There
have also been reports of CEA-producing HAC in the
literature, but not enough evidence suggests the use
of CEA levels as a diagnostic criterion. This marker
can however be used in a clinical setting to monitor
disease progression. This patient presented with an
elevated CEA that did not change in response to treat-
ment with cisplatin–etoposide. This was expected due
to the lack of any positive response to the chemothera-
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Table 2 Summary of the patient’s clinical course
Date Clinical course AFP (ng/mL) CEA (ng/mL) Imaging
April 19, 2018 Prior to treatment 1.5 32.0 Chest CT showing a 9.3× 7.2cm mass located in the upper
lobe of the right lung (RUL) PET-CT hilar lymphadenopathy
and left adrenal metastasis
June 6, 2018 Status post 2 cycles of cisplatin–
etoposide
1.5 31.7 N/A
August 29, 2018 Status post 2 cycles of pembrolizumab n/a 5.7 N/A
October 10, 2018 Status post 5 cycles of pembrolizumab n/a 5.3 Chest CT shows 45% reduction in mass
December 2018 Status post 9 cycles of pembrolizumab n/a 6.2 N/A
January 23, 2019 Status post 10 cycles of pembrolizumab n/a 17.3 Chest CT shows growth of primary mass in RUL
PET-CT shows a RUL mass measuring 8.4× 9.0cm and
a right thoracic inlet mass measuring 3.1× 3.6cm
peutic treatment. CEA levels had decreased and stabi-
lized after switching to pembrolizumab and had been
stable until December 2018, a period of 6 months.
A serial rise in CEA (Table 2) prompted a CT scan
which indicated progression at the primary site. This
evidence is suggestive that CEA could be used to clin-
ically monitor CEA-producing NSCLC.
The rarity of this type of tumors does not allow
to define a standard treatment. There is no gener-
alized consensus about the treatment of HAC, but
based on previously published case reports, surgical
resection and neoadjuvant chemotherapy is the treat-
ment of choice for non-advanced HAC of the lung
([4]; Table 1). In the case we bring forward, the pa-
tient’s stage at presentation did not make them eli-
gible for surgery and they were thus started on cis-
platin and etoposide. The use of this combination is
reported as both a primary intervention in the setting
of advanced disease or as neo-adjuvant therapy in the
setting of a resectable tumor (Table 1).
The disappointing response to chemotherapy
prompted the decision to change the treatment regi-
men to an immunotherapeutic agent. Pembrolizumab
is a PD-L1 receptor antagonist that has been approved
by the FDA for the treatment of NSCLC with high PD-
L1 expression and as first line treatment of advanced
NSCLC regardless of PD-L1 expression. The PD-L1+
immunohistochemical profile of the tumor supports
the use of pembrolizumab for treatment. This is the
first reported use of pembrolizumab in a case of hep-
atoid adenocarcinoma. We believe that this highlights
the importance of immunohistochemical analysis in
the management of HAC specifically, and NSCLC gen-
erally. We recommend that all patients with NSCLC
be investigated for immunohistochemical markers
prior to initiation of treatment, which will allow for
targeted therapy. The adoption of an immunothera-
peutic treatment regimen has allowed for a treatment
course less burdened with symptoms, 6 months af-
ter the discontinuation of cisplatin–etoposide. The
reduction in tumor activity seen in previously highly
active hilar area and left adrenal gland is indicative
of the efficacy of pembrolizumab in the management
of PD-L1 positive NSCLC. Unfortunately, the primary
mass had progressed to its approximate size at pre-
sentation and the mixed response to immunotherapy
has warranted an escalation to third line therapy
with ramucirumab and docetaxel in accordance with
FDA-approved guidelines for the management of
treatment-resistant NSCLC. As previous case reports
indicate, prognosis of HAC of the lung is poor [5],
especially for non-resectable disease (Table 1). Pa-
tient’s clinical course has spread over 10 months as
of February 10, 2019. This also indicated a promising
result for the use of immune-targeted therapy in the
management of advanced HAC of the lung.
Patient is status post 3 cycles of ramucirumab. Tol-
erating therapy well and with negative symptomatol-
ogy. Last CT shows a regression of the primary mass
in the RUL and the mass in the right thoracic inlet.
Time since diagnosis: 14 months.
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